S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The gold catalyst we’ve waited for (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NASDAQ:AKTS

Akoustis Technologies - AKTS Stock Forecast, Price & News

$2.81
-0.08 (-2.77%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.80
$2.91
50-Day Range
$2.73
$4.80
52-Week Range
$2.28
$7.13
Volume
462,815 shs
Average Volume
841,899 shs
Market Capitalization
$201.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.06

Akoustis Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
151.3% Upside
$7.06 Price Target
Short Interest
Bearish
6.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Akoustis Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3,496 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.86) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Computer And Technology Sector

465th out of 614 stocks

Telephone & Telegraph Apparatus Industry

10th out of 11 stocks


AKTS stock logo

About Akoustis Technologies (NASDAQ:AKTS) Stock

Akoustis Technologies, Inc. is a filter solutions company, which engages in the development, design, and manufacture of radio frequency (RF) filter products. It operates through the Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment is composed of engineering review services and STC-MEMS foundry services. The RF Filters segment includes amplifier and filter product sales, and grant revenue. The company was founded by Jeffrey B. Shealy in 2014 and is headquartered in Huntersville, NC.

Receive AKTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoustis Technologies and its competitors with MarketBeat's FREE daily newsletter.

AKTS Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
12 Most Promising Micro-Cap Stocks According to Analysts
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Akoustis Is Entering The Big League
Akoustis Technologies
See More Headlines
Receive AKTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoustis Technologies and its competitors with MarketBeat's FREE daily newsletter.

AKTS Company Calendar

Last Earnings
2/07/2023
Today
3/28/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Telephone & telegraph apparatus
Sub-Industry
N/A
Current Symbol
NASDAQ:AKTS
Fax
N/A
Employees
156
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.06
High Stock Price Forecast
$9.25
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+151.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-59,030,000.00
Net Margins
-287.98%
Pretax Margin
-298.02%

Debt

Sales & Book Value

Annual Sales
$15.35 million
Book Value
$1.85 per share

Miscellaneous

Free Float
67,690,000
Market Cap
$201.06 million
Optionable
Not Optionable
Beta
1.74

Key Executives

  • Jeffrey B. ShealyJeffrey B. Shealy
    President, Chief Executive Officer & Director
  • Robert Dry
    Vice President-Operations & Test
  • Kenneth BollerKenneth Boller
    Chief Financial Officer
  • David M. AicheleDavid M. Aichele
    Executive Vice President-Business Development
  • Kamran Cheema
    Chief Product Officer













AKTS Stock - Frequently Asked Questions

Should I buy or sell Akoustis Technologies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTS shares.
View AKTS analyst ratings
or view top-rated stocks.

What is Akoustis Technologies' stock price forecast for 2023?

3 analysts have issued 1-year target prices for Akoustis Technologies' shares. Their AKTS share price forecasts range from $5.00 to $9.25. On average, they expect the company's share price to reach $7.06 in the next year. This suggests a possible upside of 151.3% from the stock's current price.
View analysts price targets for AKTS
or view top-rated stocks among Wall Street analysts.

How have AKTS shares performed in 2023?

Akoustis Technologies' stock was trading at $2.82 on January 1st, 2023. Since then, AKTS shares have decreased by 0.4% and is now trading at $2.81.
View the best growth stocks for 2023 here
.

Are investors shorting Akoustis Technologies?

Akoustis Technologies saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,970,000 shares, an increase of 11.7% from the February 28th total of 4,450,000 shares. Based on an average daily volume of 806,900 shares, the short-interest ratio is presently 6.2 days.
View Akoustis Technologies' Short Interest
.

When is Akoustis Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our AKTS earnings forecast
.

How were Akoustis Technologies' earnings last quarter?

Akoustis Technologies, Inc. (NASDAQ:AKTS) issued its quarterly earnings data on Tuesday, February, 7th. The technology company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.06. The technology company had revenue of $5.87 million for the quarter, compared to the consensus estimate of $5.91 million. Akoustis Technologies had a negative trailing twelve-month return on equity of 55.85% and a negative net margin of 287.98%.

What ETF holds Akoustis Technologies' stock ?

Defiance Next Gen Connectivity ETF holds 1,220,436 shares of AKTS stock, representing 0.63% of its portfolio.

What guidance has Akoustis Technologies issued on next quarter's earnings?

Akoustis Technologies issued an update on its third quarter 2023 earnings guidance on Wednesday, February, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.04 billion-$8.21 billion, compared to the consensus revenue estimate of $7.61 million.

What other stocks do shareholders of Akoustis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Block (SQ), Editas Medicine (EDIT), Marvell Technology (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

What is Akoustis Technologies' stock symbol?

Akoustis Technologies trades on the NASDAQ under the ticker symbol "AKTS."

Who are Akoustis Technologies' major shareholders?

Akoustis Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Silverback Asset Management LLC (3.61%), Senvest Management LLC (2.47%), Needham Investment Management LLC (1.53%), Geode Capital Management LLC (1.45%), Penserra Capital Management LLC (1.42%) and Granahan Investment Management LLC (1.31%). Insiders that own company stock include Arthur Geiss, David Aichele, James Michael Mcguire, Jeffrey B Shealy, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends
.

How do I buy shares of Akoustis Technologies?

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akoustis Technologies' stock price today?

One share of AKTS stock can currently be purchased for approximately $2.81.

How much money does Akoustis Technologies make?

Akoustis Technologies (NASDAQ:AKTS) has a market capitalization of $201.06 million and generates $15.35 million in revenue each year. The technology company earns $-59,030,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does Akoustis Technologies have?

The company employs 156 workers across the globe.

How can I contact Akoustis Technologies?

Akoustis Technologies' mailing address is 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078. The official website for the company is www.akoustis.com. The technology company can be reached via phone at (704) 997-5735 or via email at bprag@delmarconsulting.com.

This page (NASDAQ:AKTS) was last updated on 3/28/2023 by MarketBeat.com Staff